We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
18 May 2018
Polyphor, clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, set the offer price for its shares in the initial public offering (“IPO”) at CHF 38 per share. The shares of the Company have commenced trading on SIX Swiss Exchange on 15 May 2018. The total placement volume, excluding the Greenshoe Option, amounts to CHF 155 million which will primarily be used to fund the continued development of Polyphor’s lead product candidate murepavadin towards regulatory approval and further progress the development of balixafortide.
VISCHER AG is acting as Swiss legal counsel to the issuer with Matthias Staehelin (Partner, Corporate) as team leader, Benedict Christ (Partner, Corporate), Angelo Imperiale (Associate, Corporate), Luzius Zumstein (Associate, Corporate), Nadia Tarolli (Partner, Tax) and Adrian Briner (Associate, Tax).
Categories: Life Sciences, Pharma, Biotech, Startup Desk, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
Attorney at Law, Swiss Certified Tax Expert (2008)
Swiss Certified Public Accountant, Swiss Certified Tax Expert
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...